Contributions of the ADNI Biostatistics Core
- PMID: 39140601
- PMCID: PMC11485306
- DOI: 10.1002/alz.14159
Contributions of the ADNI Biostatistics Core
Abstract
The goal of the Biostatistics Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been to ensure that sound study designs and statistical methods are used to meet the overall goals of ADNI. We have supported the creation of a well-validated and well-curated longitudinal database of clinical and biomarker information on ADNI participants and helped to make this accessible and usable for researchers. We have developed a statistical methodology for characterizing the trajectories of clinical and biomarker change for ADNI participants across the spectrum from cognitively normal to dementia, including multivariate patterns and evidence for heterogeneity in cognitive aging. We have applied these methods and adapted them to improve clinical trial design. ADNI-4 will offer us a chance to help extend these efforts to a more diverse cohort with an even richer panel of biomarker data to support better knowledge of and treatment for Alzheimer's disease and related dementias. HIGHLIGHTS: The Alzheimer's Disease Neuroimaging Initiative (ADNI) Biostatistics Core provides study design and analytic support to ADNI investigators. Core members develop and apply novel statistical methodology to work with ADNI data and support clinical trial design. The Core contributes to the standardization, validation, and harmonization of biomarker data. The Core serves as a resource to the wider research community to address questions related to the data and study as a whole.
Keywords: Alzheimer's Disease Neuroimaging Initiative; biomarker progression; biomarker validation; clinical trial design; data standardization.
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
Dr. Beckett, Dr. Harvey, Dr. Donohue, and Ms. Saito receive support from research grants from NIH. Dr. Harvey serves as a Statistical Advisor for
References
-
- Weiner MW, Veitch DP, Miller MJ, et al. Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Alzheimers Dement. 2023;19(1):307‐317. doi:10.1002/alz.12797 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CAPMC/ CIHR/Canada
- ALZ/Alzheimer's Association/United States
- Araclon Biotech
- AbbVie
- Transition Therapeutics
- Cogstate
- EB/NIBIB NIH HHS/United States
- Foundation for the National Institutes of Health
- Eisai Inc.
- Johnson & Johnson Pharmaceutical Research &Development LLC
- EuroImmun
- Biogen
- Alzheimer's Drug Discovery Foundation
- Servier
- Lumosity
- Bristol-Myers Squibb Company
- Piramal Imaging
- Takeda Pharmaceutical Company
- Meso Scale Diagnostics, LLC
- Novartis Pharmaceuticals Corporation
- CereSpir, Inc.
- Northern California Institute for Research and Education
- BioClinica, Inc.
- U19 AG024904/NH/NIH HHS/United States
- U19 AG024904/AG/NIA NIH HHS/United States
- GE Healthcare
- Pfizer Inc.
- Elan Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
- Eli Lilly and Company
- IXICO Ltd.
- NeuroRx Research
- Merck & Co., Inc.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- P30 AG072972/AG/NIA NIH HHS/United States
- Neurotrack Technologies
- Fujirebio
- Lundbeck
